Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after ...

The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...

Reports Q4 revenue $174.2M, consensus $155.25M. “Our 2024 results reflect solid commercial execution across the company, including continued ...

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) will likely be releasing its earnings data after the market closes ...

Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.

Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is $0.52 (+2500.0% Y/Y) and the consensus ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Shares of Supernus Pharmaceuticals stock opened at $34.59 on Wednesday. The company has a market cap of $1.91 billion, a PE ratio of 32.33 and a beta of 0.90. The business has a 50 day moving ...